The impact of RelA silencing on B2M was statistically significant, but the absolute difference was limited, which is consistent with the notion that other transcription factors, such as IRF1, facilitate the upregulation of B2M in ER+ breast cancer cells as in other cell types (67). The gene discussed is B2M; the disease is breast cancer.